Stock Pulse
DuPont de Nemours (DD) is under investigation by Chinese regulators for alleged monopolistic practices related to its Tyvek business, representing less than 1% of its 2024 net sales [5], [9], [11]. While the company maintains it did nothing wrong [7], this investigation, occurring amidst US-China trade tensions [8], [10], creates uncertainty for its operations in China, a key market [9]. Despite this, DD is focusing on innovation in healthcare, cost-saving measures, and returning value to shareholders through dividends [2], [3]. The company is also preparing for the spin-off of its Electronics business in 2025 and projects mid-single-digit organic sales growth [6]. While recent stock performance has been volatile due to trade concerns and the investigation [6], [7], [9], the company's strong dividend yield and potential for earnings growth could attract investors [2].